Table 1. Clinical characteristics of CHP-MAGE-A4 vaccinated cancer patients and their safeties and survivals after vaccinations.
| Pt No. | Code No. | Age at entry/Sex | Disease | Stage at onset | Prior therapy | Lesions at study entry | Dose (μg) | Vaccine cycle | Related adverse event (grade) | Tumor response (during first six cylcles) | Survival time (month) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 766 | 67/M | laryngeal squamous cell cancer | IV | surgery, radiotherapy | skin, bone | 100 | 4 | none | PD | 2.5 |
| 2 | 630 | 68/M | esophageal cancer | III | chemotherapy, radiotherapy | lung, liver | 100 | 10 | none | PD | 7 |
| 3 | 887 | 82/F | esophageal cancer | IV | radiotherapy | lymph node | 100 | 6 | skin reaction(I) | PD | 8.5 |
| 4 | 698 | 48/F | ovarian cancer | IIc | surgery, chemotherapy | none | 100 | 6 | skin reaction(I) | PD | 100.1* |
| 5 | 687 | 68/M | esophageal cancer | III | chemotherapy, radiotherapy | esophagus, lymph node | 300 | 4 | none | PD | 8.8 |
| 6 | 998 | 62/M | esophageal cancer | IV | chemotherapy, radiotherapy | none | 300 | 15 | skin reaction(I) | not evaluable | 68.3* |
| 7 | 1147 | 64/F | esophageal cancer | IV | surgery | lymph node | 300 | 11 | skin reaction(I) | SD | 10.3 |
| 8 | 1358 | 38/F | ovarian cancer | IIIc | surgery, chemotherapy | none | 300 | 12 | none | not evaluable | 87.4* |
| 9 | 1188 | 60/M | esophageal cancer | III | chemotherapy, radiotherapy | none | 300 | 10 | none | not evaluable | 84.2* |
| 10 | 704 | 69/M | esophageal cancer | IV | chemotherapy, radiotherapy | liver | 300 | 6 | none | PD | 4.1 |
| 11 | NMC001 | 76/M | esophageal cancer | II | chemothrapy, radiotherapy | esophagus | 300 | 6 | skin reaction(I) | PD | 16.3 |
| 12 | KIT-5 | 69/M | esophageal cancer | IV | chemotherapy, radiotherapy, immunotherapy | lung, lymph node | 100 | 14 | skin reaction(I) | PD | 7.5 |
| 13 | KIT-8 | 67/M | esophageal cancer | IV | chemotherapy, radiotherapy | primary tumor, lymph node | 100 | 7 | skin reaction(I) | PD | 3.2 |
| 14 | KIT-9 | 56/M | esophageal cancer | IIB | surgery,chemotherapy, radiotherapy | lung, lymph node | 100, (−>300) | 16 | skin reaction(I) | PD | 7.6 |
| 15 | KIT-10 | 76/F | esophageal cancer | IIIC | chemotherapy, radiotherapy | primary tumor, lymph node | 300 | 7 | skin reaction(I) | PD | 4.3 |
| 16 | KIT-11 | 64/M | esophageal cancer | IV | chemotherapy, radiotherapy | lymph node | 300 | 7 | skin reaction(I) | PD | 3.4 |
| 17 | KIT-12 | 83/M | esophageal and pharyngeal cancer | IVA | chemotherapy, radiotherapy | primary tumor | 300 | 4 | none | PD | 3.3 |
| 18 | KIT-13 | 69/M | duodenal cancer | IIIA | surgery,chemotherapy | lymph node,lung, liver | 300 | 14 | skin reaction(I) | PD | 8.2 |
| 19 | KIT-14 | 72/M | esophageal cancer | IIB | chemotherapy, radiotherapy | primary tumor | 300 | 7 | skin reaction(I) | PD | 10.9 |
| 20 | KIT-15 | 66/M | tongue squamous cell cancer | IVA | surgery,chemotherapy, radiotherapy | pleural dissemination | 300+OK432 | 6 | skin reaction(I) | PD | 4 |
| 21 | KIT-16 | 63/M | parotid cancer | IVA | surgery | pleural dissemination | 300+OK432 | 9 | skin reaction(I) | SD | 36.6 |
| 22 | KIT-17 | 66/M | esophageal cancer | IV | chemotherapy, radiotherapy | lymph node | 300+OK432 | 8 | skin reaction(I) | SD | 16 |
*alive.